Baxter BioPharma Solutions to manufacture Moderna COVID-19 vaccine doses

Baxter BioPharma Solutions and Moderna have entered an agreement for Baxter to provide fill/finish sterile manufacturing services for approximately 60-90 million doses of the Moderna COVID-19 vaccine in 2021 at its Bloomington, Indiana facility.

“Baxter is honored to provide our deep expertise in vaccine manufacturing to help partners like Moderna bolster the supply of their vaccine.”businesswire.com

• 2 sources
• businesswire.comBaxter BioPharma Solutions and Moderna Announce Agreement for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.Baxter Media ContactMar 8, 2021
• biospace.comBaxter BioPharma Solutions and Moderna Announce Agreement for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S. - BioSpaceAnnalee ArmstrongMar 8, 2021

Summarized from public sources; check the original articles before acting on it.